Subscribe
2020-04-02
Pavel Kapysh / Shutterstock.com
22 June 2021Big PharmaMuireann Bolger

SCOTUS won’t resuscitate Amarin’s Vascepa patents

Amarin has failed to persuade the US Supreme Court to consider reviving six patents on the heart medicine Vascepa (icosapent ethyl), allowing generic drugmakers Hikma Pharmaceuticals and Dr. Reddy’s Laboratories to roll out copycat products.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More on this story

Big Pharma
Amarin petitions Supreme Court to revive Vascepa patents
18 February 2021   Irish pharmaceutical company Amarin has petitioned the Supreme Court to revive its patents on its heart medication Vascepa.
Americas
SCOTUS asks for SG’s view on enablement in antibody dispute
19 April 2022   The US Supreme Court has asked the Solicitor General to wade in on a case centring on the legal concept of enablement that is the crux of an antibody patent dispute between Amgen and Sanofi.
Americas
Amarin appeals ‘skinny label’ loss
23 November 2022   Generic heart drug was found to not infringe Amarin’s blockbuster treatment earlier this year | Health insurer Health Net tied to case after allegedly promoting use of the generic.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?